Division of Merck & Co. Inc.
Latest From MSD France
NICE draft guidance says that Tecentriq in combination with chemotherapy is not cost effective in untreated advanced triple-negative breast cancer.
MSD’s Keytruda will be paid for through the Cancer Drugs Fund for use in combination with carboplatin and paclitaxel as a first-line treatment for metastatic squamous non-small-cell lung cancer.
Regulators, Industry Agree That Frequent Communication Is Key In Developing Breakthrough, PRIME Therapies
EU and US FDA regulators and industry share strategies for expediting the development of breakthrough and PRIME therapies.
India’s Biocon reported first-quarter net profit that soared by more than 70% and said it was confident of a “very successful” US trastuzumab launch, despite rival Amgen stealing a march by commercializing its own biosimilar first in the world’s largest drug market.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Merck & Co. Inc.
- Senior Management
- Michel Vounatsos, Managing Dir.
- Contact Info
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.